ExoTHERAPY
Platform Overview
The ExoTherapy platform is built on the natural biology of exosomes and differentiated by proprietary post-production loading technology designed to add therapeutic cargo without genetically engineering the exosomes or compromising their natural biological properties.
NurExone’s competitive edge lies in its ability to transform natural exosomes into nanodrugs by combining the intrinsic biological properties of exosomes with targeted molecular cargo.
This approach may support a flexible drug delivery platform for regenerative applications in central nervous system injury and, over time, additional therapeutic areas.
A proprietary platform for developing exosome-Based therapies
Exosome
API
Active Pharmaceutical Ingredient
nanodrug
What Are Exosomes?
Natural biological nanoparticles with unique advantages for regenerative therapies and drug delivery
Exosomes are nanosized biological particles released by cells as part of normal cell-to-cell communication. They carry molecular signals between cells and tissues, including RNA, proteins, lipids, and other biological cargo.
They are being studied across the life sciences as a new therapeutic modality with potential advantages including cell-free administration, off-the-shelf development, and biological delivery of selected therapeutic payloads.
Minimally invasive
Exosome-based therapies may be delivered through practical, less invasive routes, helping support clinically usable treatment approaches.
Cell-free
Because exosomes are cell-free biological particles, they may offer some of the regenerative benefits associated with stem cells in a more practical therapeutic format.
Crosses the BBB
Exosomes may help support delivery across the blood-brain barrier, an important advantage for central nervous system applications.
Potential for off-the-shelf products
Exosomes support the development of ready-to-use therapies with scalable manufacturing and broader clinical accessibility.
Loaded exosomes are exosomes carrying defined therapeutic cargo. In ExoPTEN, NurExone loads exosomes with a proprietary siRNA sequence designed to target PTEN, creating a nanodrug candidate for CNS injury.
Loaded Exosomes
NurExone uses exosomes as natural delivery vehicles for therapeutic cargo, including siRNA. This approach is designed to combine the biological properties of exosomes with the precision of defined molecular cargo.
Drug Delivery
Possible Future Indications
Potential for licensing or collaboration agreements for:
- Approved or under-development drugs that cannot currently be delivered to the brain because they can’t cross the blood-brain-barrier
- Repurpose of products in low dosing or safer manner (nanoparticles that can penetrate cells)
- Combination approaches that pair exosome delivery with selected biological or regenerative technologies.